2Preston FE,Jarvis LM,Makris M,et al.Heterogeneity of hepatitis C virus genotypes in hemophilia:relationship with chronic liver disease.Blood,1995,85:1259-1262.
4Leruez-Ville M,Nguyen QT,Cohen P,et al.Large-scale analysis of hepatitis C virus serological typing assay:effectiveness and limits.J Med Virol,1998,55:18-23.
5Stuyer L,Wyseur A,van Arnhem W,et al.Hepatitis C virus genotyping by means of 5-UR/core line probe assays and molecular analysis of untypeable samples.Virus Res,1995,38:137-157.
6Kobayashi M,C hayama K,Arase Y,et al.Enzyme-linked immunosorbent assay to detect hepatitis C virus serological groups 1 to 6.J Gastroenterol,1999,34:505-509.
7Gault E,Soussan P,Morice Y,et al.Evaluation of a new serotyping assay for detection of anti-hepatitis C virus type-specific antibodies in serum samples.J Clin Microbiol,2003,41:2084-2087.
8Songsivilai S,Kanistanon D,Dharakul T.A serotyping assay for hepatitis C virus in southeast Asia.Clin Diagn Lab Immunol,1998,5:737-739.
2Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology, 2003, 38: 645-652.
3Reddy K, Rakela J, Lopez-Talavera J, et al. Correlation between rapid virologic response, early virologic response and sustained virologic response in HCV genotype 1 patients with pegylated interferon alfa 2a and ribavirin. Gastroenterology, 2005, 128:S1540.
4Kobayashi M, Chayama K, Arase Y, et al. Enzyme-linked immunosorbent assay to detect hepatitis C virus serological groups 1 to 6. J Gastroenterol, 1999, 34:505-509.
5Hoofnagle JH, Ghany MG, Kleiner DE, et al. Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology, 2003, 38 : 66-74.
6Zeuzem S, Lee JH, Franke A, et al. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology, 1998, 27:1149-1156.
7Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pre treatment viremia. J Hepatol, 2006, 44:97-103.
8Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa- 2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med, 2005, 352:2609-2617.
